Faculty Of Medicine 6
251. A systematic review of inflammatory bowel disease in Kazakhstan: prevalence, risk factors, and genetic insights
252. A systematic review of inflammatory bowel disease in Kazakhstan: prevalence, risk factors, and genetic insights
253. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
254. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
255. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
256. What does a migraine aura look like?—A systematic review
257. Elucidating the genomic basis of rare pediatric neurological diseases in Central Asia and Transcaucasia
258. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
259. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
260. Fluvoxamine may reverse the decrease in filtering capacity that occurs in acute kidney injury by increasing IL-10 and ACE expressions and preserving AQ-2, AQ-4, CL-5, and ZO-1 expressions
261. Fluvoxamine may reverse the decrease in filtering capacity that occurs in acute kidney injury by increasing IL-10 and ACE expressions and preserving AQ-2, AQ-4, CL-5, and ZO-1 expressions
262. Mortality and Morbidity in Adults with Rheumatic Heart Disease
263. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
264. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
265. The Combined Effect of Multisensory Stimulation and Therapist Support on Physical and Mental Health of Older Adults Living in Nursing Homes: Pilot Randomized Controlled Trial
266. Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis
267. Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis
268. Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis
269. Self-reported changes in alcohol and tobacco use during COVID-19: Findings from the eastern part of WHO European Region
270. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
271. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
272. Evaluation of National Immunization Technical Advisory Groups (NITAGs) of middle-income countries in the WHO European Region; a synopsis
273. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
274. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
275. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
276. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
277. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
278. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
279. The effectiveness of yoga as a form of exercise in the management of rheumatic diseases
280. Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry
281. Sociodemographic Factors Associated with Physical Functioning in Elderly Males and Females from Serbia: Population-Based Modeling Study
282. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE v survey in 16 European countries
283. Outpatient pediatric care during the COVID-19 pandemic, Almaty, Kazakhstan 2021–2022
284. Outpatient pediatric care during the COVID-19 pandemic, Almaty, Kazakhstan 2021–2022
285. The burden of COVID-19 in primary care of Almaty, Kazakhstan, 2021–2022
286. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
287. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
288. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
289. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
290. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
291. HIV infection should no longer be detected at late stages in Italy
292. HIV infection should no longer be detected at late stages in Italy
293. A global action agenda for turning the tide on fatty liver disease
294. A global action agenda for turning the tide on fatty liver disease
295. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
296. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
297. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
298. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
299. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
300. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
1 4 5 6 7 8 14